These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15953827)

  • 1. Environmental toxins and alpha-synuclein in Parkinson's disease.
    Liu Y; Yang H
    Mol Neurobiol; 2005; 31(1-3):273-82. PubMed ID: 15953827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
    Olanow CW; Brundin P
    Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
    Büeler H
    Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new role for α-synuclein in Parkinson's disease: Alteration of ER-mitochondrial communication.
    Guardia-Laguarta C; Area-Gomez E; Schon EA; Przedborski S
    Mov Disord; 2015 Jul; 30(8):1026-33. PubMed ID: 25952565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease.
    Esteves AR; Gozes I; Cardoso SM
    Biochim Biophys Acta; 2014 Jan; 1842(1):7-21. PubMed ID: 24120997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein-induced mitochondrial dysfunction in isolated preparation and intact cells: implications in the pathogenesis of Parkinson's disease.
    Bir A; Sen O; Anand S; Khemka VK; Banerjee P; Cappai R; Sahoo A; Chakrabarti S
    J Neurochem; 2014 Dec; 131(6):868-77. PubMed ID: 25319443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease?
    Lee SJ
    Antioxid Redox Signal; 2003 Jun; 5(3):337-48. PubMed ID: 12880487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    Curr Opin Investig Drugs; 2001 May; 2(5):657-62. PubMed ID: 11569943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular insights into Parkinson's disease.
    Rochet JC; Hay BA; Guo M
    Prog Mol Biol Transl Sci; 2012; 107():125-88. PubMed ID: 22482450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of Parkinson's disease: Mitochondria, alpha-synuclein and much more….
    Rouaud T; Corbillé AG; Leclair-Visonneau L; de Guilhem de Lataillade A; Lionnet A; Preterre C; Damier P; Derkinderen P
    Rev Neurol (Paris); 2021 Mar; 177(3):260-271. PubMed ID: 33032797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Α-synuclein misfolding and Parkinson's disease.
    Breydo L; Wu JW; Uversky VN
    Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Environment, mitochondria, and Parkinson's disease.
    Sherer TB; Betarbet R; Greenamyre JT
    Neuroscientist; 2002 Jun; 8(3):192-7. PubMed ID: 12061498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein and Parkinson's disease: a proteomic view.
    Fasano M; Lopiano L
    Expert Rev Proteomics; 2008 Apr; 5(2):239-48. PubMed ID: 18466054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease.
    Xu Y; Deng Y; Qing H
    J Neurochem; 2015 Oct; 135(1):4-18. PubMed ID: 26134497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2012 Nov; 53(9):1791-806. PubMed ID: 22967820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
    Li B; Zhang Y; Yuan Y; Chen N
    Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SUMO-regulated mitochondrial function in Parkinson's disease.
    Guerra de Souza AC; Prediger RD; Cimarosti H
    J Neurochem; 2016 Jun; 137(5):673-86. PubMed ID: 26932327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson's Disease.
    Bobela W; Aebischer P; Schneider BL
    Biomolecules; 2015 Oct; 5(4):2675-700. PubMed ID: 26501339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.